Zai Lab Ltd., a pharmaceutical company based in Shanghai and Cambridge, Mass., has recently achieved significant milestones in China. On May 12, the company gained approval from the National Medical Products Administration (NMPA) for Bristol Myers Squibb Co.'s Augtyro (repotrectinib) for the treatment of lung cancer. This approval marks a major advancement in Zai Lab's portfolio of cancer therapies. Additionally, on May 14, the NMPA accepted the supplemental Biologics License Application (BLA) for subcutaneous Vyvgart (efgartigimod alfa SC) with priority review. Vyvgart is a novel treatment for certain autoimmune diseases. The acceptance of the BLA is a significant step forward in bringing this therapy to patients in China. These achievements have generated positive momentum for Zai Lab, as evidenced by a recent stock purchase by one of the company's executives. [f1cb661b]